Valeo Financial Advisors LLC Sells 499 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Valeo Financial Advisors LLC lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 53.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 433 shares of the company’s stock after selling 499 shares during the period. Valeo Financial Advisors LLC’s holdings in IDEXX Laboratories were worth $240,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of IDXX. Moneta Group Investment Advisors LLC lifted its position in IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock worth $3,038,192,000 after acquiring an additional 7,441,162 shares during the period. Alliancebernstein L.P. raised its stake in shares of IDEXX Laboratories by 6.4% in the second quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock worth $1,804,428,000 after purchasing an additional 214,529 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of IDEXX Laboratories by 1.4% during the first quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company’s stock worth $971,569,000 after purchasing an additional 26,197 shares during the period. Blair William & Co. IL boosted its position in IDEXX Laboratories by 0.7% in the third quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock valued at $524,700,000 after buying an additional 7,812 shares during the last quarter. Finally, Brown Advisory Inc. increased its holdings in IDEXX Laboratories by 2.2% in the 3rd quarter. Brown Advisory Inc. now owns 1,161,124 shares of the company’s stock worth $507,725,000 after buying an additional 24,741 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold a total of 43,524 shares of company stock valued at $24,871,960 over the last ninety days. Corporate insiders own 2.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IDXX. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. The Goldman Sachs Group boosted their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a report on Tuesday, January 30th. Finally, Barclays lifted their price target on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $591.50.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $491.29 on Tuesday. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The business’s 50 day moving average is $545.29 and its two-hundred day moving average is $508.55. The company has a market capitalization of $40.80 billion, a P/E ratio of 48.79, a P/E/G ratio of 3.83 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. During the same quarter last year, the firm posted $2.05 EPS. The business’s revenue was up 8.8% on a year-over-year basis. Analysts expect that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.